EngitixlicensingGSK taps Engitix’s platform in liver fibrosis deal worth up to £44.5m upfrontLondon-based Engitix Ltd has entered a strategic research collaboration and option agreement with GSK to discover and validate new therapeutic targets for liver fibrosis regression, adding another pharma … more ➔
licensingRoche bets on BTK degradation in $2.3bn Nurix dealSwiss pharma giant Roche has signed a global licensing and collaboration agreement with US biotech Nurix Therapeutics to co-develop and co-commercialise bexobrutideg, an oral Bruton’s tyrosine kinase … more ➔
clinical dataADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control armSwiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events … more ➔
InvestmentLilly and Boehringer pause $2bn German investments over planned drug-spending curbsThe announcements came almost simultaneously and send a clear signal to policymakers and the industry: both US pharmaceutical group Eli Lilly and German-based Boehringer Ingelheim are calling planned … more ➔
fundraisingOna Therapeutics bags $86.6m Series B for stealth ADC pushBarcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development. more ➔
Start-upIngenix raises €13m to scale AI drug development engineWarsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC. more ➔
FinancingIMU Biosciences secures US$53m to decode the immune systemLondon-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further … more ➔
clinical dataAbivax delivers Phase 3 ulcerative colitis win, but safety concerns trigger market sell-offParisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary … more ➔
Elnur Amikishiyev-stock.adobe.comStart-upA fresh start for Molecular Health: technology core becomes start-up LuceraA restart from within: Molecular Health is becoming Lucera. After years of shifting corporate fortunes, a substantial part of Heidelberg-based Molecular Health is continuing in a new form. An investor … more ➔
clinical dataGreywolf reports early responses with oral ERAP1 inhibitor in solid tumoursOxford-based Greywolf Therapeutics has reported early clinical activity for its first-in-class oral ERAP1 inhibitor GRWD5769 in combination with the anti-PD-1 antibody cemiplimab across six solid tumour … more ➔
Engitix
Elnur Amikishiyev-stock.adobe.com